SHR-A1904, ADC yo mu bwoko bwa CLDN18.2-Targeting, igaragaza imikorere myiza yo kurwanya kanseri y’igifu/gastroesophageal Junction: Ibisubizo by’igerageza ry’icyiciro cya mbere

Ku ya 16 Nyakanga, ikinyamakuru mpuzamahanga cy’urwego rwo hejuru cyitwa Nature Medicine cyasohoye amakuru y’ubushakashatsi kuri SHR-A1904, umuti uhuza imiti n’uturemangingo (ADC) wibasira claudin 18.2 (CLDN18.2), mu kuvura kanseri y’igifu cyangwa kanseri y’uturemangingo tw’igifu (GC/GEJC). Abashakashatsi bakoze igerageza rya mbere mu bantu, ry’icyiciro cya mbere, kugira ngo basuzume akamaro ka SHR-A1904 ku barwayi 95 bavuwe mbere barwaye kanseri ya G/GEJ ya CLDN18.2.

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Indangamuntu ya WeChat: 17801183037

Email：myimmnet@163.com

Claudin-18 isoform 2 (CLDN18.2), poroteyine ifatanye mu buryo bufatika igaragara mu gice cy’imbere cy’igifu kitari kibi kandi ikagaragara ku buso bw’uturemangingo tw’ikibyimba mu gihe cy’impinduka mbi, ni ingenzi mu kuvura kanseri y’igifu n’umuyoboro w’igifu (G/GEJ). SHR-A1904 ni antibody-drug conjugate igizwe na antibody monoclonal CLDN18.2, ADN topoisomerase I inhibitor payload hamwe n’agace gashobora gucibwamo gashingiye kuri peptide.

Mu cyiciro cyo kwiyongera kw'umuti (0.6–8.0 mg kg−1), uburozi bugabanya urugero rw'umuti bwagaragaye ku barwayi babiri bari kuri 4.8 mg kg−1 (icyorezo cya febrile neutropenia cyo mu cyiciro cya 3 n'ubwiyongere bwa bilirubin mu maraso bwo mu cyiciro cya 3) naho ku murwayi umwe bari kuri 6.0 mg kg−1 (ikibyimba cy'igifu cyo mu gifu cyo mu cyiciro cya 3). Igipimo ntarengwa cyihanganirwa nticyagezweho, kandi 6.0 mg kg−1 na 8.0 mg kg−1 byatoranijwe kugira ngo bikoreshwe mu buryo bwo kongera imikorere y'imiti. Ingaruka mbi z'ubuvuzi zagaragaye ku barwayi bose 95, akenshi bafite amaraso make (72 (75.8%), isesemi (64 (67.4%), hypoalbuminemia (61 (64.2%)) no kugabanuka k'umubare w'uturemangingo tw'amaraso (56 (58.9%)). Byongeye kandi, abarwayi 59 (62.1%) bahuye n'ingaruka mbi z'umuti zo mu cyiciro cya 3 cyangwa hejuru. Nta mpfu zijyanye n'umuti zagaragaye. Mu barwayi bapimwe ibisubizo, igipimo cy’ubwitabire cyagaragajwe cyari 24.2% (95% igihe cy’icyizere (CI), 11.1–42.3) kuri 6.0 mg kg−1 na 25.0% (95% CI, 12.1–42.2) kuri 8.0 mg kg−1. Impuzandengo y’ubuzima buzira umuze yari amezi 5.6 (95% CI, 3.0–6.9) kuri 6.0 mg kg−1 na 5.8 (95% CI, 3.0–8.6) kuri 8.0 mg kg−1. Mu gusoza, SHR-A1904 yagaragaje umutekano uhamye kandi itera imbaraga mu kurwanya kanseri ku barwayi ba kanseri ya G/GEJ ya CLDN18.2, bikaba bikwiye ko hakorwa iperereza ryimbitse.

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Indangamuntu ya WeChat: 17801183037

Email：myimmnet@163.com